Noninvasive Hemoglobin Monitoring for Maintaining Hemoglobin Concentration Within the Target Range

Sponsor
Seoul National University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03816514
Collaborator
(none)
130
1
2
20.1
6.5

Study Details

Study Description

Brief Summary

The primary aim of this study is to evaluate whether pulse oximetry based noninvasive hemoglobin (SpHb) monitoring can reduce the incidence of hemoglobin (Hb) level out of the target range in adult patients undergoing major surgery with the potential risk of bleeding.

Condition or Disease Intervention/Treatment Phase
  • Procedure: SpHb monitoring
  • Procedure: Conventional management
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Use of Noninvasive Hemoglobin Monitoring for Maintaining Hemoglobin Concentration Within the Target Range During Major Surgery: A Randomized Controlled Trial
Actual Study Start Date :
Mar 4, 2019
Actual Primary Completion Date :
Nov 2, 2020
Actual Study Completion Date :
Nov 6, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: SpHb monitoring group

In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.

Procedure: SpHb monitoring
Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring

Active Comparator: Control group

In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.

Procedure: Conventional management
Conventional management without SpHb monitoring

Outcome Measures

Primary Outcome Measures

  1. The incidence of deviation from the target hemoglobin range [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    (The number of laboratory samples with the result hemoglobin concentrations were out of the target range)/(Total number of laboratory samples that performed during intra-operative periods)

Secondary Outcome Measures

  1. The percentage extent of deviation from the target hemoglobin range [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    The percentage extent of deviation of laboratory hemoglobin out of the prespecified target range

  2. Number of Point-of-care (POC) sampling during surgery [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    Number of Point-of-care (POC) sampling for measurement of hemoglobin concentration. In SpHb group, POC sampling will be done according to SpHb level. In control group, POC sampling will be done at discretion of anesthesiologist.

  3. Accuracy of the SpHb value [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    Standard Laboratory hemoglobin measurement will be used as reference. Laboratory measurements will be done every 30 minute during surgery

  4. Number of patients who receive intra-operative transfusion [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    Number of patients who were transfused with pRBCs intraoperatively

  5. Total volume of intravenous fluids given [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    Total volume of intravenous fluids given intra-operatively

  6. Total volume of pRBCs transfused [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    Total volume of pRBCs transfused intra-operatively

  7. Time for transfusion delay [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    Time from the determination of transfusion to actual transfusion, in minutes

  8. Incidence of intraoperative hypotension [Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia]

    hypotension is defined as SBP < 80% of baseline SBP

  9. laboratory total hemoglobin value, at postoperative day 1 [at postoperative day 1]

    total hemoglobin value measured by standard laboratory method

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients with ASA physical status class I, II, III, who scheduled to undergo elective non-cardiac major surgery with more than moderate risk of bleeding under general anesthesia or spinal anesthesia.

  • Eligible Surgery include: Spine surgery, bone tumor surgery, Total Hip Replacement, ovarian cancer surgery, cervical cancer surgery, radical cystectomy, open retroperitoneal mass excision, Radical Retropubic Prostatectomy, explorative laparotomy for abdominal mass excision, abdominal aortic aneurysm repair

  • Patients who are requiring an arterial catheter as a part of their standard care.

Exclusion Criteria:
  • Patients with preexisting deformity or skin condition that would impede sensor placement

  • Patients with allergies to the adhesive sensor material

  • Patients with uncorrected preoperative anemia (preoperative hemoglobin < 7 g/dL)

  • Patients who were not suitable for participation in the opinion of the study investigator.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Seoul national university hospital Seoul Korea, Republic of 110-744

Sponsors and Collaborators

  • Seoul National University Hospital

Investigators

  • Principal Investigator: Jin-Tae Kim, MD, PhD, Seoul National University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jin-Tae Kim, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT03816514
Other Study ID Numbers:
  • H-1811-039-986
First Posted:
Jan 25, 2019
Last Update Posted:
Dec 22, 2020
Last Verified:
Dec 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 22, 2020